Assessing Green Thumb Industries (CNSX:GTII) Valuation After Strong Q1 2026 Earnings And Share Price Recovery

Green Thumb Industries (CNSX:GTII) just released first quarter 2026 results, reporting sales of US$300.19 million and net income of US$15.4 million. These figures put earnings firmly in focus for cannabis stock investors. See our latest analysis for Green Thumb Industries. The earnings release appears to sit against a mixed price backdrop, with a 1-day share price return of 2.5% and a 90-day share price return of 10.81% contrasting with a year to date decline of 11.35%. The 1-year total shareholder return of 24.71% highlights that recent momentum follows a longer recovery from deeper five year losses. If this earnings move has you rethinking where growth could come from next, it may be worth scanning for other companies with similar potential using the 3 top founder-led companies With sales at US$300.19 million, net income at US$15.4 million and a value score of 5, the key question is whether Green Thumb Industries is still trading at a discount or if the market is already pricing in future growth. Most Popular Narrative: 45.6% Undervalued With Green Thumb Industries closing at CA$9.84 against a narrative fair value of CA$18.08, the current price sits well below that valuation anchor. The sustained scarcity of institutional investment due to federal legal ambiguity presents a near-term valuation discount; any progress on federal policy reform or regulatory clarity would unlock access to broader capital markets and institutional ownership, a structural catalyst likely to benefit Green Thumb's equity valuation and capacity for reinvestment in growth. Read the complete narrative. Want to see what is baked into that gap? Revenue expectations, margin rebuild and future earnings multiples all thread together in this narrative. The key is how those moving parts interact over time. Result: Fair Value of CA$18.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh ongoing price compression in key markets and the higher capital spending plans. Both factors could pressure margins and test this undervalued thesis. Find out about the key risks to this Green Thumb Industries narrative. Another Valuation Check: Earnings Multiple Versus Fair Ratio The narrative model points to Green Thumb Industries trading 46% below fair value, yet the current P/E of 12.9x sits above the estimated fair ratio of 11.2x, even though it is below the North American pharmaceuticals average of 14.6x and the peer average of 44.8x. Is that discount a cushion or a signal that expectations are still optimistic? For a closer look at how this earnings multiple compares with what the numbers suggest the ratio could move toward, and how that shapes potential upside and downside, See what the numbers say about this price — find out in our valuation breakdown. CNSX:GTII P/E Ratio as at May 2026Next Steps With the mix of cautious and optimistic signals so far, it helps to look at the data yourself and pressure test both sides of the story. To weigh the upside against the concerns, start with the 3 key rewards and 1 important warning sign. Looking for more investment ideas? If Green Thumb Industries has sharpened your thinking, do not stop here. Use a few focused screens to spot other opportunities that could fit your playbook. Hunt for potential value outliers by scanning the 11 high quality undervalued stocks that combine solid fundamentals with prices that still look forgiving. Strengthen the quality of your watchlist by reviewing the solid balance sheet and fundamentals stocks screener (8 results) built around companies with sturdier financial footing. Get ahead of the crowd by checking the screener containing 8 high quality undiscovered gems before others start paying attention to them. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free